HPGC(SH:600664)2017-10-26 16:00Financial Performance - Revenue for the first nine months was CNY 9.21 billion, a decrease of 10.96% year-on-year[6] - Net profit attributable to shareholders decreased by 56.84% to CNY 263.78 million for the first nine months compared to the same period last year[6] - Basic earnings per share decreased by 56.85% to CNY 0.1058 for the first nine months compared to the same period last year[6] - Total operating revenue for Q3 2017 was approximately ¥3.04 billion, a decrease of 5.78% compared to ¥3.23 billion in Q3 2016[29] - Net profit for Q3 2017 was a loss of approximately ¥67.51 million, compared to a profit of ¥249.68 million in Q3 2016, marking a significant decline[31] - The total operating profit for the first nine months was approximately ¥1.44 billion, down 36.7% from ¥2.27 billion year-on-year[34] - The company achieved an investment income of approximately ¥251.28 million for the first nine months, a decrease from ¥1.35 billion year-on-year[35] Cash Flow - Operating cash flow decreased by 95.34% to CNY 106.47 million for the first nine months compared to the same period last year[6] - Cash flow from operating activities dropped by 95.34% to ¥106,469,128.97, mainly due to decreased cash sales and the timing of receivables[10] - The cash flow from operating activities for the first nine months was approximately ¥106.47 million, a significant decrease from ¥2.29 billion in the previous year[38] - Operating cash inflow for the period (January to September) was CNY 1,840,018,222.10, a decrease of 53.7% compared to CNY 3,978,179,771.27 in the same period last year[40] - Net cash flow from operating activities was CNY 164,227,834.13, down 83.3% from CNY 985,103,349.15 year-on-year[40] - Cash inflow from investment activities totaled CNY 374,671,264.94, a decline of 74.5% compared to CNY 1,468,952,380.07 in the previous year[40] - Cash outflow from financing activities was CNY 1,291,474,196.87, resulting in a net cash flow from financing activities of -CNY 1,291,474,196.87[41] Assets and Liabilities - Total assets decreased by 9.83% to CNY 13.57 billion compared to the end of the previous year[6] - Total current assets decreased from CNY 10,059,427,776.11 at the beginning of the year to CNY 8,840,551,148.25, a decline of approximately 12.1%[21] - Total liabilities decreased from CNY 6,754,640,834.89 to CNY 6,304,859,622.90, a decline of approximately 6.6%[23] - Total equity decreased from CNY 8,298,104,076.79 to CNY 7,268,059,501.45, a decrease of about 12.3%[23] - The company’s fixed assets decreased from CNY 4,101,318,985.83 to CNY 3,796,092,432.57, a decline of about 7.4%[22] Shareholder Information - The total number of shareholders reached 101,029 by the end of the reporting period[8] - The largest shareholder, Harbin Pharmaceutical Group Co., Ltd., holds 46.00% of the shares[8] Stock and Corporate Actions - The company completed the grant registration of 9.195 million restricted stocks to 174 incentive objects, increasing total shares from 2,541,243,276 to 2,550,438,276[7] - The company is planning a significant asset restructuring involving its subsidiary, which is still in the planning stage and carries substantial uncertainty[13] - The company’s stock was suspended from trading starting September 28, 2017, due to major matters related to its controlling shareholder, Harbin Pharmaceutical Group[12] Expenses - The company reported a significant increase in development expenditures from CNY 21,659,617.00 to CNY 58,348,330.21, an increase of approximately 169.5%[22] - The company incurred sales expenses of approximately ¥18.07 million for the first nine months, a decrease of 81.8% compared to ¥98.92 million in the previous year[34]